[1] 叶莺,严延生. 耐多药结核的流行概况[J]. 疾病控制杂志, 2008,12(1):63-65. [2] Turner RD. Cough in pulmonary tuberculosis: existing knowledge and general insights[J]. Pulm Pharmacol Ther, 2019,23(55):89-94. [3] Kundu S,Marzan M,Gan SH,et al. Prevalence of antibiotic-resistant pulmonary tuberculosis in Bangladesh: a systematic review and meta-analysis[J]. Antibiotics (Basel), 2020,9(10):710. [4] 何昱颖,胡屹,陈玮,等.2014—2018年贵州省利福平耐药结核病的危险因素及治疗转归分析[J].中华传染病杂志,2021,39(5):289-294. [5] Dong S, Shen X, Xia Z, et al. Changes in the epidemic of pulmonary tuberculosis in Shanghai from 1992 to 2016[J]. Trop Med Int Health, 2019,24(2):220-228. [6] Wang JL,Zhou XL,Han C,et al. Prevalence of invasive aspergillosis in suspected pulmonary tuberculosis at a referral tuberculosis hospital in Shandong, China[J]. Epidemiol Infect,2020,5(148):1-15. [7] 中华医学会,中华医学会杂志社,中华医学会全科医学分会,等.肺结核基层诊疗指南(2018年)[J].中华全科医师杂志,2019,18(8):709-717. [8] 中国防痨协会专业委员会.结核病诊断细菌学检验规程[M].北京:中国教育文化出版社,2006:30-96. [9] 张旭霞,梁晨,姚丛,等.北京地区2008—2010年肺结核病复发流行病学和机制分析[J].国际呼吸杂志,2020,40(9):679-683. [10] Sinshaw W, Kebede A, Bitew A, et al. Prevalence of tuberculosis, multidrug resistant tuberculosis and associated risk factors among smear negative presumptive pulmonary tuberculosis patients in Addis Ababa, Ethiopia[J]. BMC Infect Dis,2019,19(1):641. [11] Li T,Shi T,Sun Y,et al. Molecular characteristics of drug-resistance Mycobacterium tuberculosis strains isolated from extra pulmonary tuberculosis sites[J]. Enferm Infecc Microbiol Clin (Engl Ed),2021,39(4):168-173. [12] 陈兴,陈勇毅.阳江市肺结核患者耐药状况调查及影响因素分析[J].实用药物与临床,2019,22(3):321-324. [13] 于海娟,赵梅,王佳月,等.肺结核患者结核杆菌耐药情况及耐多药结核病的危险因素[J].中国感染控制杂志,2020,19(1):58-62. [14] 高天慧,舒薇,高静韬,等.254例耐药肺结核患者克拉霉素耐药情况及影响因素分析[J].中国防痨杂志,2020,42(3):259-265. [15] 时翠林,牛广豪,王霞芳,等.耐药结核病治疗药物研究进展[J].中华结核和呼吸杂志,2020,43(1):58-63. [16] 刘盛盛,王莲芝,唐神结.耐多药和利福平耐药结核病化学治疗研究进展[J].中华结核和呼吸杂志,2020,43(4):371-375. [17] Sharma M, Kumar D, Bohra GK, et al. Study of the prevalence of multidrug-resistant pulmonary tuberculosis (MDR-TB) in Western Rajasthan using line probe assay[J]. J Family Med Prim Care,2020,9(2):1093-1097. [18] Wang P, Gu J, Yang J, et al. Effect of Xpert MTB/RIF on the treatment of multi-drug-resistant or rifampicin-resistant tuberculosis screened out from re-treatment pulmonary tuberculosis patients, a prospective cohort study[J]. Ann Palliat Med,2020,9(2):239-246. [19] 马进宝,任斐,曾令城,等.2015—2019年西安市680例耐多药结核病患者耐药情况分析[J].中国防痨杂志,2020,42(6):83-87. [20] 陈其琛,雷宇,刘国标.2013—2017年广州市户籍耐多药肺结核流行特征[J].实用预防医学,2020,27(2):219-223. [21] 赵亚玲,黎舒,邱媛.2012—2016年南宁市耐多药肺结核高危人群筛查情况分析[J].应用预防医学,2019,25(1):4. [22] 何伏华,冯地忠,丁守华.2014—2018年淮安市非结核定点医院疑似肺结核患者转诊追踪和定诊情况分析[J].预防医学论坛,2019,25(7):62-64,67. [23] 冯地忠,何伏华,丁守华,等.2012—2017年淮安市学生肺结核流行病学分析[J].现代预防医学,2019,46(3):411-414.
2022, Vol. 29 
